pharmaphorum

MARCH 17, 2022

The uptake of digital health tools during the pandemic has been enormous due to improved access they provide to healthcare. In this article, Ben Hargreaves asks whether there are gaps in those utilising these solutions and what action is being taken to address this. Digital health has a tremendous capacity to transform the healthcare industry, with the ability to provide easy access to a multitude of services and new types of therapies.

145

145

Outsourcing Pharma

MARCH 17, 2022

The medication adherence specialist is joining IT4Anxiety, a project focused on dealing with anxiety in patients with mental disorders, via technology.

59

59

pharmaphorum

MARCH 17, 2022

Researchers in Germany are have found a possible link between mild COVID-19 infection and an increased risk of type 2 diabetes, although they caution the signal needs further investigation. The team from Heinrich Heine University in Dusseldorf and healthcare data science company IQVIA identified the possible correlation after analysing health records from 8.8 million patients registered at 1,171 health practices across Germany, including almost 36,000 who had been diagnosed with mild COVID-19.

Hospitals 114

Hospitals 114

Outsourcing Pharma

MARCH 17, 2022

The latest news on software, manufacturing solutions, partnerships, and more includes IQVIA, TFF Pharmaceuticals, Quotient Sciences and other key companies.

52

52

Speaker: Chris Antypas and Josh Halladay

Access to limited distribution drugs and payer contracts are key to pharmacy expansion. But how do you prepare your operations to take the next step? Meaningful data: Collect and share clinical data regarding outcomes, utilization, and more Reporting: Limited distribution models require efficient tracking and reporting systems Workflows: Align workflows with specific pharma and payer contractual requirements For in-depth, expert insights on pharmacy expansion, watch this webinar from Inovalon.

pharmaphorum

MARCH 17, 2022

After months of debate about the validity of its phase 3 clinical trials for Alzheimer’s therapy Aduhelm, Biogen has published the results in a peer-review journal, allowing physicians to look at the data and judge its efficacy and safety. The choice of journal looks like it could, however, add to the controversy surrounding the troubled drug, which has been used to treat only a few patients since its accelerated approval by the FDA last June.

FDA 59

FDA 59

Pharma Times

MARCH 17, 2022

The sub-variant combines mutations from both Omicron and Delta

70

70

Pharma Times

MARCH 17, 2022

The NHS has not met the 18-week target for people to receive planned treatment in England since February 2016

40

40

pharmaphorum

MARCH 17, 2022

The global market for life sciences is changing rapidly. Fuelled by technological advancements and a global pandemic, there are more opportunities than ever for companies to get innovative and life-saving therapies to the patients that need them. But when it comes to marketing new therapies, the seemingly complex nature of global markets can be intimidating, with regulatory, cultural and language insight required to commercialise a brand image across different markets.

52

52

pharmaphorum

MARCH 17, 2022

AstraZeneca has resolved a lingering liability following its takeover of Alexion with an agreement to pay $775 million to settle a patent dispute with Chugai Pharma, Roche’s Japanese subsidiary. The long-running disagreement focuses on Ultomiris (ravulizumab), Alexion’s long-acting complement C5 inhibitor for paroxysmal nocturnal hemoglobinuria and haemolytic uraemic syndrome (HUS).

52

52

pharmaphorum

MARCH 17, 2022

GE Healthcare says a longstanding effort to develop a unified data management system for the health sector is close to fruition, with partners now being sought to road-test the platform. Dubbed the Edison Digital Health Platform, the new system is designed to bring together from just about any source within the healthcare ecosystem, backed by an artificial intelligence engine, so it can be used to support decision-making and improve patient care.

Hospitals 59

Hospitals Patient Care 59

Speaker: Dr. Ben Locwin - Biopharmaceutical Executive & Healthcare Futurist

What will the future hold for clinical research? A recent draft from the FDA provides valuable insight. In "Optimizing the Dosage of Human Prescription Drugs and Biological Products for the Treatment of Oncologic Diseases," the FDA notes that "targeted therapies demonstrate different dose-response relationships compared to cytotoxic chemotherapy, such that doses below the Maximum Tolerated Dose (MTD) may have similar efficacy to the MTD but with fewer toxicities.

FDA